Charles Schwab’s VITAE PHARMACEUTICALS INC COMMON STOCK VTAE Stock Holding History

Charles Schwab’s Portfolio VTAE Stock Details VTAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-85,017	Closed	-$1.78M	–	3105
2016 Q3	$1.78M	Buy	85,017 +4,226	+5%	+$48.7K	﹤0.01%	2197
2016 Q2	$872K	Buy	80,791 +47,602	+143%	+$407K	﹤0.01%	2395
2016 Q1	$221K	Buy	33,189 +612	+2%	+$5.57K	﹤0.01%	2871
2015 Q4	$590K	Buy	32,577 +5,128	+19%	+$70.6K	﹤0.01%	2576
2015 Q3	$303K	Buy	27,449 +1,331	+5%	+$14.1K	﹤0.01%	2824
2015 Q2	$377K	Buy	26,118 +11,652	+81%	+$158K	﹤0.01%	2787
2015 Q1	$170K	Buy	14,466 +812	+6%	+$11K	﹤0.01%	2984
2014 Q4	$228K	Buy	+13,654	New	+$200K	﹤0.01%	2949

Charles Schwab's VTAE Position: Q4 2016 in Review

Charles Schwab sold out of VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) in Q4 2016, closing a stake of 85,017 shares — an estimated $1.78M sold.

Charles Schwab first reported a position in VTAE in Q4 2014 and held it in 8 quarters. The position peaked at $1.78M in Q3 2016. 0 funds tracked by Wall St. Rank hold VTAE as of Q4 2016.

Charles Schwab reported no remaining VITAE PHARMACEUTICALS INC COMMON STOCK position as of Q4 2016 after selling out during the quarter.
Charles Schwab sold 85,017 VITAE PHARMACEUTICALS INC COMMON STOCK shares in Q4 2016, an estimated $1.78M.
Charles Schwab first reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK in Q4 2014 and held it in 8 quarters.
Charles Schwab's VITAE PHARMACEUTICALS INC COMMON STOCK position peaked at $1.78M in Q3 2016.
0 funds tracked by Wall St. Rank held VITAE PHARMACEUTICALS INC COMMON STOCK as of Q4 2016.

Based on Charles Schwab's 13F filing for Q4 2016, filed 13 Feb 2017.